BioSpace News Archive

Tiziana Life Sciences Ltd. today announced that the Company was highlighted in a FORBES article highlighting foralumab, the Company’s unique intranasal monoclonal antibody, which is currently in clinical development to treat multiple sclerosis and a range of other neurodegenerative diseases.

Chemomab Therapeutics Ltd. today announced the company will discuss its fourth quarter and full-year 2022 financial results and provide a business update on Friday, March 31, 2023, at 8:00 am Eastern Time.

BridgeBio announced today that preliminary data on the Company’s muscle tissue-based bioassay measuring glycosylated ⍺DG in LGMD2I patients will be featured in an oral presentation and posters at the MDA 2023 Annual Meeting, taking place in Dallas, Texas on March 19 - 22, 2023.

Nuvectis Pharma, Inc. today announced upcoming presentations for NXP800 and NXP900 at the upcoming 2023 American Association for Cancer Research Meeting (2023 AACR), taking place from April 14th to April 19th in Orlando, Florida.

Advanced Medaesthetic Partners (AMP), a leading provider of medical aesthetic services, today announces its strategic investment in Destination Aesthetics™ (DA), Northern California’s Premier Medical Spa.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data, showing that initiation of TREMFYA ® (guselkumab) was associated with greater treatment persistence a compared to secukinumab or ixekizumab in bio-naïve and bio-experienced patientsb living with moderate to severe plaque psoriasis (PsO), based on pairwise analysesc of real-world data.

Kyowa Kirin Co., Ltd. will be presented in two posters at the upcoming American Academy of Dermatology (AAD) 2023 Annual Meeting to be held March 17-22, 2023, in New Orleans, Louisiana, USA.

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a developer of Next Generation Chemotherapies (NGCs), today announced that the Company has dosed the first patient in its NGC-Capecitabine (combination of PCS6422 and capecitabine) 300 mg dose group.

According the latest data released at the Clinical Trials Implied Approval section on the website of China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), Likang Life Sciences (hereinafter referred to as “Likang”) has received implied approval for the clinical trial of its personalized neoantigen-targeted vaccine for advanced solid tumors, LK101 Injection.

BRAINBox Solutions today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance to issue to the company a broad patent covering a specific set of biomarkers that correlate to specific neuroimaging findings by standard or advanced MRI methods.